الاستراتيجيات لإدارة النقص الحاد في معدات الحماية الشخصية خلال جائحة فيروس COVID-19
This guidance provides considerations and a series of options that can be used to inform country strategies in managing any shortages of personal prote...ctive equipment.Re-use and reprocessing of single-use PPE must be a last resort temporary measure to be adopted until stocks are replenished. The WHO and other agencies are currently conducting research about this and further guidance will likely become available soon.
more
These guidelines are intended to help diverse actors, including donors and program implementers, develop and fund the programs to help landmine victims heal, recover and resume their roles as productive and contributing members of their societies. Intended to address the care and rehabilitation of t...hose victims who have suffered physical injury from landmines, many of the recommendations apply as well to support for other persons with disabilities
more
Nearly 90 years after Simon Kuznets first introduced Gross Domestic Product (GDP) for the limited purpose of measuring economic growth (by measuring the monetary value of all local goods and services within a given period of time), calls continue to mount for decision-makers to stop using GDP and it...s derivate, Gross National Income (GNI), for purposes far beyond their original design. This is particularly true in the case of the development assistance architecture, where these indicators are used as proxies to measure a nation’s overall well-being and, in some cases, eligibility for external funding. The GNI-based classification system has recently even been suggested by some Member States as a criterion to access to medicines in the new WHO Pandemic Agreement.
more
A general consensus exists that as a country develops economically, health spending per capita rises and the share of that spending that is prepaid through government or private mechanisms also rises. However, the speed and magnitude of these changes vary substantially across countries, even at simi...lar levels of development. In this study, we use past trends and relationships to estimate future health spending, disaggregated by the source of those funds, to identify the financing trajectories that are likely to occur if current policies and trajectories evolve as expected.
Methods
We extracted data from WHO's Health Spending Observatory and the Institute for Health Metrics and Evaluation's Financing Global Health 2015 report. We converted these data to a common purchasing power-adjusted and inflation-adjusted currency. We used a series of ensemble models and observed empirical norms to estimate future government out-of-pocket private prepaid health spending and development assistance for health. We aggregated each country's estimates to generate total health spending from 2013 to 2040 for 184 countries. We compared these estimates with each other and internationally recognised benchmarks.
Findings
Global spending on health is expected to increase from US$7·83 trillion in 2013 to $18·28 (uncertainty interval 14·42–22·24) trillion in 2040 (in 2010 purchasing power parity-adjusted dollars). We expect per-capita health spending to increase annually by 2·7% (1·9–3·4) in high-income countries, 3·4% (2·4–4·2) in upper-middle-income countries, 3·0% (2·3–3·6) in lower-middle-income countries, and 2·4% (1·6–3·1) in low-income countries. Given the gaps in current health spending, these rates provide no evidence of increasing parity in health spending. In 1995 and 2015, low-income countries spent $0·03 for every dollar spent in high-income countries, even after adjusting for purchasing power, and the same is projected for 2040. Most importantly, health spending in many low-income countries is expected to remain low. Estimates suggest that, by 2040, only one (3%) of 34 low-income countries and 36 (37%) of 98 middle-income countries will reach the Chatham House goal of 5% of gross domestic product consisting of government health spending.
Interpretation
Despite remarkable health gains, past health financing trends and relationships suggest that many low-income and lower-middle-income countries will not meet internationally set health spending targets and that spending gaps between low-income and high-income countries are unlikely to narrow unless substantive policy interventions occur. Although gains in health system efficiency can be used to make progress, current trends suggest that meaningful increases in health system resources will require concerted action.
Funding
Bill & Melinda Gates Foundation.
more
Tuberculosis (TB) is among the top ten most common causes of death globally and as a single infectious disease it top among infectious diseases. Furthermore, it is noted as the top causes of death among people infected with the human immunodeficiency virus (HIV). Despite recent decreases in the numb...er of notified cases, Namibia still has a high TB burden and is included among the top 30 high-burden TB countries by the World Health Organisation (WHO). In the 2018 Global TB Report, the estimated incidence rate of TB in Namibia was 423/100,000. The same report estimated that 60 people per 100,000 populations died of TB in Namibia, which is a concern, for a disease that is curable and preventable.
more
Zambia has completed the implementation of the National TB Strategic Plan (2017-2021) that set in motion the TB elimination agenda in Zambia through coordinated and accelerated TB response. During this period, the National TB and Leprosy Programme (NTLP) registered tremendous success.
The NTLP is ...poised to attain the ambitious goal pronounced by the government of eliminating TB by 2030, in line with the Sustainable Development Goals (SDGs) and the World Health Organization End TB Strategy. The programme exponentially increased TB notifications from as low as 35,922 people with TB in 2018 to 40,726 in 2020 and in 2021 the TB notifications rose to 50,825 (a 25% increase against 2020 performance). The NTLP also registered incredible success in sustaining high TB Preventive Treatment (TPT) initiations among persons living with HIV and a high TB treatment success rate among drug-susceptible TB cases. New and relapse TB notifications in children below 15 years increased by 43%, from 2,724 in 2020 to 3,890 in 2021. TB notifications ratio between children aged 0-4 and 5-14 was 0.9, an improvement from what we achieved in 2018 (the ratio was 0.7). The proportion of TB patients who are HIV positive continued to decrease, reaching 34% in 2021 from 39% in 2020. Sustained increases in TB notifications, treatment success rate, and TPT initiations have resulted in a rapid decrease in the TB incidence rate that reached 307 per 100,000 population in 2021 against a rate of 391 in 2015.
more
Social and Behaviour Change Communication (SBCC) is essential for the effective control, prevention and elimination of malaria. The 2018–2030 Strategic Framework for Malaria SBCC guides countries and partners in strengthening capacities, refining strategies and sharing best practices, all of which... are aligned with the WHO Global Technical Strategy for Malaria. Despite progress, malaria continues to threaten billions of people, and success hinges on access to interventions and behavioural change. This framework emphasises advocacy, technical guidance and tools to ensure that SBCC is prioritised and resourced as an essential element in the global fight against malaria.
more
This Implementation Kit (I-Kit) is designed to support SBCC and Malaria in Pregnancy (MiP) programme managers in improving their communication strategies, particularly those targeting healthcare workers. It provides practical guidance on four key planning areas and emphasises the significant health ...risks that malaria poses to mothers and newborns. The I-Kit highlights evidence-based WHO interventions and addresses barriers to access, demand and the delivery of MiP services by providers. Despite progress in reducing malaria, uptake of preventive measures remains low, highlighting the need for targeted advocacy and improved SBCC strategies.
more
Lancet 2024; 403: 533–44
R21/Matrix-M was well tolerated and offered high efficacy against clinical malaria in African children. This
low-cost, high-efficacy vaccine is already licensed by several African countries, and recently received a WHO policy
recommendation and prequalification, offerin...g large-scale supply to help reduce the great burden of malaria in sub-
Saharan Africa.
more
BioDrugs. 2023 Sep 20;37(6):737–756. doi: 10.1007/s40259-023-00623-4
There are many malaria vaccine candidates in development, with more than a dozen of these in clinical development. RTS,S/AS01 (also known as Mosquirix) is the most advanced malaria vaccine and was shown to have modest efficacy ...against clinical malaria in phase III trials in 5- to 17-month-old infants. Following pilot implementation trials, the World Health Organisation has recommended it for use in Africa in young children who are most at risk of infection with P. falciparum, the deadliest of the human malaria parasites.
more
Issued by the Ministers of Health of High Burden High Impact (HBHI) countries in Africa. Yaounde Declaration.
Ministers committed to strengthening their health systems, stepping up domestic resources, enhancing multisectoral action and ensuring a robust accountability mechanism,” notes Dr Daniel ...Ngamije, Director of the WHO Global Malaria Programme. “This is the kind of leadership the world must rally behind.
more
Noncommunicable diseases (NCDs) are chronic medical conditions that are not spread from person to person. Unlike infectious diseases, which are caused by bacteria, viruses, or other pathogens, NCDs are typically long-lasting and result from a combination of genetic, physiological, environmental, and... behavioral factors. NCDs are the leading cause of death worldwide and responsible for over 70% of global deaths each year. Over 80% of these deaths occur in low- and middle-income countries (WHO). Noncommunicable diseases pose a serious threat to global health because they are widespread, costly, largely preventable, and responsible for the majority of deaths worldwide. Reducing their impact requires coordinated efforts in prevention, early detection, and healthcare system strengthening, particularly in lower-income countries. The Toolbox on Noncommunicable Diseases (NCDs) can play a vital role in strengthening Global Healthcare systems by providing centralized, reliable, and up-to-date health information and resources like clinical guidlelines, education material as well as tools for prevention and health promotion.
more
The ongoing global pandemic of SARS-CoV-2 (Covid-19) poses unique diagnostic and clinical management challenges in regions where seasonal epidemic-prone diseases are endemic. Diseases such as dengue, malaria, seasonal influenza, leptospirosis, chikungunya, scrub typhus and bacterial infections often... present with febrile syndromes that mimic or co-exist with SARS-CoV-2 infection, complicating diagnosis and treatment. This document provides guidelines for preventing, diagnosing and managing such co-infections. A high level of suspicion is essential during the monsoon and post-monsoon seasons, taking into account region-specific disease prevalence. While the WHO's case definition for SARS-CoV-2 is broad and sensitive, the need for parallel testing for co-infections, in accordance with the protocols of the MoHFW, ICMR, NVBDCP and NCDC, is necessitated by overlapping clinical features. Ensuring the availability of reliable rapid diagnostic kits and applying integrated clinical and laboratory approaches are crucial to improving patient outcomes in the context of concurrent infections.
Accessed on 26/08/2025.
more
This document, issued by the United Nations Medical Directors in July 2021, outlines vaccination and malaria prophylaxis recommendations for UN personnel travelling on official business and UN healthcare workers. The guidance aims to minimise the risk of vaccine-preventable diseases and malaria by f...ocusing on three key areas:(1) routine vaccines, such as those for influenza, measles, polio, hepatitis B, varicella and SARS-CoV-2 (the virus that causes the disease known as 'Covid-19'), which are recommended for all staff regardless of their destination;
(2) destination-based measures, including mandatory vaccines (e.g. yellow fever, meningitis and polio), recommended vaccines depending on regional risks (e.g. cholera, typhoid, hepatitis A and rabies) and WHO-advised malaria prevention through mosquito protection and chemoprophylaxis. The third area covers vaccines for healthcare workers with direct patient or laboratory exposure, including hepatitis B, influenza, diphtheria, pertussis and others. The recommendations emphasise the importance of pre-travel medical consultations, adherence to host country requirements, and individualised risk assessments.
more
Tuberculosis (TB) remains a significant global health challenge, with an estimated annual death rate of approximately one per 100,000 people in countries with low TB prevalence. Rapid reductions in TB cases and deaths worldwide depend on research breakthroughs, including the development of new vac...cines. There has recently been an increase in political commitment, as evidenced by two UN high-level meetings on TB in 2018 and 2023. The 2023 political declaration reaffirmed the goals set out in the UN Sustainable Development Goals and the WHO's End TB Strategy, and established new targets for the period 2023–2027
more
In this guide, the African Palliative Care Association (APCA) has put together evidence‑based information on the use of specific opioids commonly used in the management of moderate‑to‑severe pain to manage both cancer and non‑cancer pain. APCA hopes that this guide will be a useful tool i...n aiding health professionals at all levels of healthcare delivery to assess and manage pain using opioids. All opioids included in this guide are listed on the WHO model list of essential medicines but we remind readers that oral morphine is the standard opioid of choice for managing moderate‑to‑severe pain and we recommend that it should be made available at all times.
more
On 13 August 2024, the Africa Centres for Disease Control (Africa CDC) declared the multi-country mpox outbreak a public health emergency of continental security, with strong recommendations to improve surveillance and vaccine deployment in all AU Member States. On 14 August 2024, the WHO Director-G...eneral declared mpox outbreak a public health emergency of international concern (PHEIC).
more
On 13 August 2024, the Africa Centres for Disease Control (Africa CDC) declared the multi-country mpox outbreak a public health emergency of continental security, with strong recommendations to improve surveillance and vaccine deployment in all AU Member States. On 14 August 2024, the WHO Director-G...eneral declared mpox outbreak a public health emergency of international concern (PHEIC).
more
The handbook is the starting point for anyone interested in learning about and understanding the key principles and concepts of supply chain management for health commodities. Concepts described in this handbook will help those responsible for improving, revising, designing, and operating all or par...t of a supply chain. The addendum provides an overview of health care supply chain management in the humanitarian response context, to help supply chain managers better prepare and deliver to the people who need relief during a crisis.
more
This study was aimed to ascertain the clinical profile and management of patients with ischemic heart disease (IHD) and/or peripheral artery disease (PAD). In this observational and cross-sectional study developed in 80 hospitals throughout Spain, consecutive adults with stable IHD and/or PAD were i...ncluded. A total of 1089 patients were analyzed, of whom 65.3% had only IHD, 17.8% PAD and 16.9% both. A total of 80.6% were taking only one antiplatelet agent, and 18.2% were on dual antiplatelet therapy (mainly aspirin/clopidogrel). Almost all patients were taking ≥1 lipid lowering drug, mainly moderate-to-high intensity statins. IHD patients took ezetimibe more commonly than PAD (43.9% vs. 12.9%; p < 0.001). There were more patients with IHD that achieved blood pressure targets compared to PAD (<140/90 mmHg: 67.9% vs. 43.0%; p < 0.001; <130/80 mmHg: 34.1% vs. 15.7%; p < 0.001), LDL-cholesterol (<70 mg/dL: 53.1% vs. 41.5%; p = 0.033; <55 mg/dL: 26.5% vs. 16.0%; p = 0.025), and diabetes (HbA1c < 7%, with SGLT2i/GLP1-RA: 21.7% vs. 8.8%; p = 0.032). Modifications of antihypertensive agents and lipid-lowering therapy were performed in 69.0% and 82.3% of patients, respectively, without significant differences between groups. The use of SGLT2i/GLP1-RA was low. In conclusion, cardiovascular risk factors control remains poor among patients with IHD, PAD, or both. A higher use of combined therapy is warranted.
more